RBN-2397 - 10mM in DMSO, high purity , CAS No.2381037-82-5

Item Number

R422794

• Synonyms: RBN-2397 | Atamparib | 2381037-82-5 | RBN2397 | Atamparib [INN] | Atamparib [USAN] | B1MW2ME77A | 4-[[(2S)-1-[3-oxo-3-[4-[5-(trifluoromethyl)pyrimidin-2-yl]piperazin-1-yl]propoxy]propan-2-yl]amino]-5-(trifluoromethyl)-1H-pyridazin-6-one | (S)-5-((1-(3-Oxo-3-(4-(5-(triflu
• Specifications & Purity: 10mM in DMSO
• Biochemical and Physiological Mechanisms: RBN-2397 is a potent, selective and orally active NAD+ competitive inhibitor PARP7 with IC50 of <3 nM and Kd of <0.001 μM. RBN-2397 has the potential for the research of tumor treatment.
• Storage Temp: Store at -80°C
• Shipped In: Ice chest + Ice pads

Product Description

Information

RBN-2397 RBN-2397 is a potent, selective and orally active NAD+ competitive inhibitor PARP7 with IC50 of <3 nM and Kd of <0.001 μM. RBN-2397 has the potential for the research of tumor treatment.

Targets

PARP7 (Cell-free assay); PARP7 (Cell-free assay) <0.001 μM(Kd); <3 nM

In vitro

RBN-2397 restores cytosolic nucleic acid sensing and blocks cell proliferation in a human lung cancer cell line.

In vivo

RBN-2397 causes complete regressions in human NSCLC NCI-H1373 xenografts and dose-dependent pharmacodynamic effects. RBN-2397 induces tumor-specific adaptive immune memory in CT26 syngeneic model with durable complete responses.

Cell Research(from reference)

Cell lines：NCI-H1373 human lung cancer cells 

Concentrations：0.4 nM to 1000 nM 

Incubation Time：24 h